Date: 2012-09-24
Type of information: Licensing agreement
Compound: antibodies targeting fibroblast growth factor 2 (FGF2)
Company: Roche (Switzerland) Galaxy Biotech (USA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
development
commercialisation
Action mechanism: Fibroblast growth factor 2 (FGF2) is overexpressed in many types of cancer, and for some tumor types a high level of FGF2 expression correlates with poor clinical outcome. FGF2 has been shown to stimulate not only angiogenesis but also lymphangiogenesis, which may be important in cancer metastasis. Galaxy has developed a novel antibody that neutralizes the biological activity of FGF2, and in published scientific work has shown that the antibody effectively inhibits the growth of certain tumors in animal models.
Disease: undisclosed cancer
Details: Roche has licensed exclusive worldwide development and commercialization rights to Galaxy Biotech’s antibodies targeting fibroblast growth factor 2 (FGF2) for the treatment of cancer.
Financial terms: Under the terms of the agreement, Galaxy will receive an $8 million license fee, and milestone payments contingent on various preclinical, clinical, and regulatory development events, as well as royalties on product sales.
Latest news:
